Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD8601 · 1 trial · 1 indication
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
Values are classified as high if they are above the normal reference range, based on local lab reference ranges.
| Arm | Type | Description |
|---|---|---|
| Low dose AZD8601 (3 mg) | EXPERIMENTAL | 8 patients will be randomised to receive 3 mg AZD8601 |
| High dose AZD8601 (30 mg) | EXPERIMENTAL | 8 patients will be randomised to receive 30 mg AZD8601 |
| Placebo | PLACEBO_COMPARATOR | 8 patients will be randomised to receive placebo injections |
| Name | Type | Description |
|---|---|---|
| AZD8601 | DRUG | AZD8601 solution for injection, 0,5 mg/mL and 5 mg/mL will be given as 30 injections of 0.1 mg (3 mg per patient), or 1 mg (30 mg per patient) respectively on a single occasion |
| Placebo | DRUG | Placebo for AZ8601 injection for solution will be given as 30 injections per patient on a single occasion |
Inclusion Criteria: For inclusion in the study patients should fulfil the following criteria at Visit 1 and/or 2: 1\. Provision of signed and dated informed consent prior to any study specific procedures Males and females: 1. Males must be surgically sterile or using an acceptable method of cont...
Top 20 of 31 competitors
AZD8601 is an investigational small molecule being developed for heart failure. It is a cardiovascular therapeutic that has been studied in patients undergoing coronary artery bypass grafting, or CABG, surgery. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
AZD8601 is being developed by AstraZeneca PLC, a multinational pharmaceutical company traded on the NASDAQ under the ticker symbol AZN. AstraZeneca is conducting clinical trials to evaluate the safety and efficacy of AZD8601 in patients with heart failure.
AZD8601 is in Phase 2 clinical development. A Phase 2 study of AZD8601 in CABG patients with heart failure has been completed. The drug is investigational and has not received regulatory approval for any indication.
AZD8601 has been studied in one clinical trial, registered as NCT03370887, titled 'AZD8601 Study in CABG Patients.' This Phase 2, randomized, double-blind, placebo-controlled trial enrolled 11 participants with heart failure and was conducted in the United States, Finland, Germany, Netherlands, and Sweden. The trial has been completed.
No, AZD8601 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for heart failure. The completed Phase 2 trial, NCT03370887, evaluated AZD8601 in CABG patients, but the drug has not yet received marketing authorization from regulatory agencies.